RAPID ALERT

DRAP ALERT No: I/S/11-24-44

CRACKDOWN AGAINST FALSIFIED / ILLEGAL PRODUCTS

Date: 08th November, 2024.

Target Audience:

- National Regulatory Field Force of DRAP and Provincial Drug Control Departments.
- Healthcare Professionals (Physicians, Pharmacists & Nurses).
- General Public

Alert Summary:

The Directorate of Drugs Control (DDC) Punjab has identified the following falsified products in the market. The samples of these products were also analyzed by provincial Drug Testing Laboratories in Punjab. The details of the identified products are as under:

S#	Product Name	Composition	Batch No.	Manufactured by (as per label claim)	Lab Test Results
1	Ativan 2mg Tablets Reg# 000084	Lorazepam	17C7019	Purported to be manufactured by Pfizer Pakistan Ltd, Karachi Pakistan	Spurious
2	Klozen 5 mL Eye Drops Reg# 040124	Tobramycin 0.3%, Dexamethasone 0.1%	134	Purported to be manufactured by Zinta Pharmaceutical Industry, Hayatabad, Peshawar	Spurious
3	S-Kyne 10mg Tablets Reg# Nil	Dydrogesterone	566	Purported to be manufactured by Weather Folds pharmaceuticals, Hattar	Spurious & Misbranded
4	Efaston 10mg Tablets Reg# 31067	Dydrogesterone	064835	Purported to be Manufactured by Lahore Chemical & Pharmaceutical Works (Pvt) Ltd. Lahore	Spurious
5	Dydowen 10mg Tablets Reg# 101507	Dydrogesterone	462	Purported to be Manufactured by Weather Folds Pharmaceuticals, Hattar	Spurious
6	Phenobar 30mg Tablets Reg# 018862	Phenobarbitone	QA030	Purported to be Manufactured by Star Laboratories (Pvt) Ltd (Human Healthcare Division) 23-KM Multan Road Lahore	Spurious

DRAP, Islamabad + 92 051 9255969 gsms@dra.gov.pk

S#	Product Name	Composition	Batch No.	Manufactured by	Test Results
7	Duphaston 10mg Tablets Reg# 006654	Dydrogesterone	230672	Purported to be Manufactured by Highnoon Laboratories Ltd. Marketed by Abbot Laboratories (Pakistan) Ltd, Lahore	Spurious

Risk Statement:

The impact of the use of falsified / Substandard products may lead to sub-optimal therapeutic effects whereas the use of a spurious product will lead to therapy failure or other associated problems.

Action initiated:

The field force under the administrative control of DRAP and Provincial Drug Control departments has been directed to immediately conduct market surveys for the detection of the presence and removal of the mentioned batches from the market.

Advice for Healthcare Professionals:

DRAP requests increased vigilance within the supply chains of institutions/pharmacies/healthcare facilities likely to be affected by batches of mentioned products. All pharmacists and chemist working at distributions and pharmacies should immediately check their stocks and stop supplying mentioned products. Adverse reactions or quality problems experienced with the use of these products are to be reported to the National Pharmacovigilance Centre (NPC), DRAP using Adverse Event Reporting Form or online through this link. Further information of reporting problems to DRAP is available on this link.

Advice for Consumers / general public:

Consumers should stop using products bearing the affected batch number(s) and shall contact to their physician or healthcare provider if they have experienced any problems that may be related to taking or using this drug product, and report the incident to Drug Regulatory Authority of Pakistan/ National Pharmacovigilance Centre.

Drug Regulatory Authority of Pakistan
محفوظ، موئثر اور معیاری اشیائے علاج

DRAP, Islamabad
+ 92 051 9255969
gsms@dra.gov.pk